Drug Profile
Research programme: integrin inhibitors - Indalo Therapeutics
Alternative Names: CWHM-12Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Saint Louis University
- Developer Indalo Therapeutics; Saint Louis University
- Class Small molecules
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis